Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Branded Generics Market Size Changed, over the years?

The market size of branded generics has seen significant expansion in the last few years. The market’s value is expected to rise from $363.49 billion in 2024 to $397.19 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this growth during the historical period include cost efficiency and affordability, expiration of patents, market outreach and expansion, government strategies and policies, and healthcare reforms.

How Much Will the Branded Generics Market Be Worth in 2029?

The market for branded generics is anticipated to experience significant expansion in the upcoming years, reaching a size of $601.4 billion in 2029, with a compound annual growth rate (CAGR) of 10.9%. This growth in the projected timeline can be credited to the increasing demand for generic biologics, escalating incidences of chronic diseases, expansion of emerging markets, and the emphasis on biosimilars. The future trends to watch include strategic alliances and collaborations, technological evolution, focus on chronic ailments, market consolidation, and a patient-centric approach.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which is the Largest Company in the Branded Generics Market?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

What Are the Main Market Drivers in the Branded Generics Industry?

As chronic diseases become more prevalent, they will stimulate an increase in the growth rate of the branded generics market. The unhealable but treatable nature of chronic diseases is escalating due to factors such as increased usage of tobacco products, subpar nutrition habits, lack of physical activity, oversuse of alcohol, among other things. Globally, consumers prefer branded generics in the management of chronic diseases because they are more affordable than standard medications. For instance, the World Health Organization (WHO), a health organization based in Switzerland, highlighted in September 2022 that noncommunicable diseases (NCDs) or chronic diseases accounted for 41 million deaths, constituting 74% of global deaths annually. Consequently, with the escalating prevalence of chronic diseases, demand in the branded generics market is projected to surge during the forecast period.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

How Is the Branded Generics Market Segments Structured?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

What Strategic Trends Are Transforming the Branded Generics Market?

The trend of strategic alliances is shaping the branded generics market significantly. Firms engaged in branded generics are forging alliances with appropriate businesses in order to leverage mutual resources and penetrate new market domains. Biocon Ltd., an Indian pharmaceutical firm, reflected this in its alliance with Tabuk Pharmaceuticals in September 2024. With a focus on creating high-quality biopharmaceuticals customized for diabetes treatment, Biocon took responsibility for the development and production of GLP-1 products. At the same time, Tabuk Pharmaceuticals obtained the rights to market authorization and took up the job of registering, importing, and promoting these products, especially in the Middle Eastern region, primarily Saudi Arabia. Provisions for future extensions to other GLP products beyond the initial offerings were also included in the deal, offering a wider variety of diabetes care options. The aim of this partnership is to provide innovative health solutions that enhance patient welfare in Saudi Arabia and neighbouring regions, reflecting the commitment of both companies to elevate healthcare accessibility. Tabuk Pharmaceuticals, based in Saudi Arabia, brings to market both branded and generic pharmaceutical offerings.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Global Regions Offer the Highest Growth in the Branded Generics Market?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

This Report Delivers Insight On:

1. How big is the branded generics market, and how is it changing globally?

2. Who are the major companies in the branded generics market, and how are they performing?

3. What are the key opportunities and risks in the branded generics market right now?

4. Which products or customer segments are growing the most in the branded generics market?

5. What factors are helping or slowing down the growth of the branded generics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model